Ponatinib and other clinically approved inhibitors of Src and Rho-A kinases abrogate dengue virus serotype 2- induced endothelial permeability.

Ponatinib 和其他经临床批准的 Src 和 Rho-A 激酶抑制剂可消除登革病毒 2 型诱导的内皮通透性